You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信降中國中藥(00570.HK)評級至「中性」 下調目標價至4.4元
阿思達克 07-14 10:51
瑞信發表報告指,中國中藥(00570.HK)發盈警料上半年淨利潤預計將按年下降50至60%,因中藥配方顆粒業務疲軟。報告指,集團下半年將重點幫助政府發布更多國家或省級中藥顆粒產品標準,公司預計下半年業績將較上半年明顯改善。 該行預料,中國中藥下半年收入將按年下降10%,將其2022至2024年度每股盈利預測下調49%/54%/54%,目標價由4.8元下調至4.4元,評級亦由「跑贏大市」降至「中性」,主為預計中藥配方顆粒業務持續受壓,而相關集中採購的實施會在較長時間內對全國產生影響。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account